Drugs / HRS-4029
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06905314 | Apr → Oct 2025 overdue | ischemic stroke | Beijing Suncadia Pharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-4029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06905314 ↗ |
| Route | Intravenous | “single intravenous dose administration” NCT06905314 ↗ |